GO
Loading...

FDA

More

  • Merrill Settles With Massachusetts on Auction Debt Thursday, 21 Aug 2008 | 1:27 PM ET

    Merrill Lynch reached a settlement with Massachusetts over auction-rate securities, the latest in a string a accords between regulators and Wall Street firms over the $330 billion market that collapsed in February

  • Cuomo Threatens to Sue Merrill Over Auction-Rate Debt Thursday, 21 Aug 2008 | 9:52 AM ET

    Merrill Lynch has until Friday to settle an auction-rate securities case with New York Attorney General Andrew Cuomo's office or it will face a lawsuit, Cuomo warned during a CNBC interview.

  • Merck Drug Gets Mixed Review from Medical Journal Wednesday, 20 Aug 2008 | 5:03 PM ET

    Two prominent articles in a major medical journal are examining the cost benefits and safety of an expensive, controversial vaccine for a sexually-transmitted disease and cancer.

  • U.S. Seeks Stronger Warnings For Amylin's Byetta Monday, 18 Aug 2008 | 3:57 PM ET
    Amylin

    U.S. health regulators are seeking stronger warnings about the risk of pancreatitis after the deaths of two patients taking Amylin Pharmaceuticals' injectable diabetes drug Byetta, sending the company's shares down as much 16 percent.

  • Big Pharma Stocks: Real Rally Or One Day Wonder? Wednesday, 9 Jul 2008 | 11:19 AM ET
    Pharma Stocks

    One day does not a full-fledged sector rotation make, but yesterday the big pharma stocks put on a show and in the early going today the curtain hasn't fallen. Pfizer even broke above 18 bucks!

  • Fourth of July fireworks

    FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."

  • FDA Delivers One-Two Punch To Merck & Lilly Wednesday, 25 Jun 2008 | 11:11 AM ET
    FDA

    For the second time in three days the Food and Drug Administration has delayed making a decision on drugs that it had put on a fast track. First, the agency put off a ruling on Lilly's bloodthinner Effient and then this morning Merck announced the FDA is not ready to approve its cervical cancer vaccine Gardasil for older women.

  • Bear Stearns Fund Managers Likely to be Indicted Thursday, 19 Jun 2008 | 5:55 AM ET

    The indictment of two Bear Stearns hedge fund managers for securities fraud is expected to be announced later on Thursday in connection with a fund tied to the subprime lending market, CNBC has learned.

  • Broadcom Co-Founder Faces Drug, Fraud Charges Thursday, 5 Jun 2008 | 6:01 PM ET
    Henry Nicholas III

    Broadcom co-founder Henry T. Nicholas III was indicted Thursday on fraud, conspiracy and drug charges—including allegations he spiked the drinks of technology executives and customer representatives with ecstasy and maintained a warehouse for ecstasy, cocaine and methamphetamine.

  • Sex and The the City

    You can get a steady diet of all things ASCO (American Society of Clinical Oncology) on CNBC and here at CNBC.com, so I'm gonna blog about something totally different. Well, it does have to do with cancer prevention. Specifically, staving off cervical cancer and/or the sexually transmitted disease known as HPV, which is the leading cause of cervical cancer.

  • Ex-Credit Suisse Banker Gets 10 Years Jail Sentence Saturday, 31 May 2008 | 7:32 AM ET

    A former Credit Suisse investment banker convicted of leaking inside information about pending mergers was sentenced to 10 years in prison by a federal judge Friday.

  • ImClone & Bristol To "FLEX" Muscles At ASCO Friday, 30 May 2008 | 11:42 AM ET
    ImClone - Erbitux

    The American Society of Clinical Oncology annual meeting, which starts today in Chicago, couldn't get any bigger for ImClone Systems and its Erbitux partners Bristol-Myers Squibb and the German Merck (no relation to the U.S.-based Merck).

  • John F. Marshall spent decades teaching at business schools and watching his students parlay his lessons into fortunes on Wall Street. But when he and another professor reached for some of those riches themselves, events took a startling turn, the authorities say.

  • Merck Wins Appeals in Three Vioxx Cases Thursday, 29 May 2008 | 10:57 AM ET

    Appeals courts in New Jersey and Texas on Thursday scrapped verdicts against drug maker Merck stemming from some of the earliest trials involving its once popular painkiller Vioxx.

  • The Great Pfizer Smokeout Thursday, 22 May 2008 | 11:20 AM ET
    Chantix

    It just keeps getting worse. Pfizer, which is staring down the loss of a $13 billion-a-year drug (Lipitor) in the 2010-11 timeframe, needs the rest of its product portfolio and its drug development pipeline to be firing on all cylinders.

  • Bush Won't Veto Bill Halting Shipments to Oil Reserve Thursday, 15 May 2008 | 10:50 AM ET

    The White House said that President Bush would not veto a final bill from Congress that orders a halt to filling the Strategic Petroleum Reserve while oil prices are very high.

  • J&J Stent Ad Under Fire in Medical Journal Wednesday, 14 May 2008 | 5:01 PM ET
    Johnson & Johnson

    Two cardiologists write in "The New England Journal of Medicine" that Johnson and Johnson's first-of-its kind TV commercial for a heart stent is aimed at "millions of people who are ill-equipped to make judgments" about the device.

  • Merck Plans to Reduce US Sales Force by 1,200 Monday, 5 May 2008 | 4:58 PM ET

    Merck, whose earnings have been hurt by patent expirations and declining sales of its Vytorin cholesterol fighter, said Monday it will eliminate another 1,200 members of its U.S. sales force as part of a restructuring begun in late 2005.

  • Merck Warned by FDA over Manufacturing Plant Wednesday, 30 Apr 2008 | 11:51 AM ET

    Merck says it has received a warning letter from the Food and Drug Administration over concerns at one of its major vaccine manufacturing plants.

  • Genentech, Biogen Idec Shares Hit by Study Results Tuesday, 29 Apr 2008 | 12:07 PM ET

    Genentech and Biogen Idec said a key study of Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.